CAMP4 Therapeutics Corp. (CAMP), a clinical-stage biotechnology company that went public in 2024, anticipates 2025 to be a crucial year, with a key clinical trial catalyst expected in the second half of the year.
The company is pioneering a new class of RNA medicines to increase targeted gene expression, with the potential to provide meaningful clinical benefits for prevalent diseases where gene upregulation is likely to be effective. Its lead drug candidate is CMP-CPS-001, being developed for the treatment of Urea Cycle Disorders.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.